Surface expression and modulation of ADAM10.

<p>A. The constitutive surface expression of ADAM10 was monitored on Hodgkin’s Lymphoma (L428), pancreatic ductal adenocarcinoma (Panc89), fibrosarcoma (HT1080) and cervical carcinoma (HeLa) cell lines. Unstimulated cells were stained with an isotype control or anti-ADAM10 mAb (clone AD214Y) and PE-conjugated anti-mouse second step antibodies. Histograms display fluorescence intensities against relative cell numbers. B. Activation-dependent alterations in ADAM10 surface abundance were monitored on tumor cells (also including U266B1 myeloma cells) at the indicated time points after stimulation with TPA and Ionomycin. For each time point, cells were stained with anti-ADAM10 mAb and PE-conjugated anti-mouse second step antibodies. Individual data points represent geometric mean values calculated from individual histograms using CellQuestPro. C. The indicated leukemic and untransformed T cell populations were analyzed for constitutive expression of ADAM10 as described for panel A. D. Activation-induced alterations of ADAM10 on Jurkat variants or cloned T cells were analyzed upon stimulation with TPA and Ionomycin as described for B.